News about "API Manufacturing"

Anuh Pharma Gets Prequalification Nod from WHO for Anti-Malarial Bulk Drug

Anuh Pharma receives World Health Organization (WHO) prequalification for Amodiaquine Hydrochloride API, an essential anti-malarial medicine used in combination therapies for Plasmodium falciparum malaria.

API Manufacturing | 06/05/2026 | By News Bureau

Dr. Reddy's Laboratories Wins Health Canada Nod for Generic Semaglutide Injection

Dr. Reddy's Laboratories secures Health Canada approval for generic semaglutide injection, becoming the first to gain market authorisation in Canada ahead of the review timeline.

API Manufacturing | 29/04/2026 | By News Bureau

Supriya Lifescience Receives US FDA EIR with VAI Status for Lote Parshuram Facility

Supriya Lifescience receives US FDA EIR with VAI classification for its Lote Parshuram facility, closing the February 2026 audit inspection cycle.

API Manufacturing | 23/04/2026 | By News Bureau

Ofichem Group Unifies Global Brands Under Single Identity to Streamline Pharma Partnerships

Ofichem consolidates its global brands under one identity to deliver integrated pharmaceutical development and supply solutions.

API Manufacturing | 11/04/2026 | By News Bureau

Agno Pharma Acquires Actylis's CDMO Manufacturing Asset

Agno Pharma has acquired Actylis’s CDMO manufacturing asset, the legacy Cascade Chemistry business based in Eugene, Oregon, strengthening Agno’s U. cGMP API development and manufacturing capabilities.

API Manufacturing | 19/01/2026 | By News Bureau |  173

FDA Announces New ANDA Prioritisation Pilot to Support US Generic Drug Manufacturing and Testing

More than half of pharmaceuticals distributed in the US are manufactured overseas. Further, the US is reliant on overseas sources for Active Pharmaceutical Ingredients (APIs). As of 2025, only nine percent of API manufacturers are in the US, compared to 22 percent in China and 44 percent in India.

API Manufacturing | 06/10/2025 | By Dineshwori |  157

Lilly Plans to Build USD 6.5 Billion Facility to Manufacture APIs in Texas

Eli Lilly will invest USD 6.5 billion to set up a new API manufacturing facility in Houston, Texas—its eighth US site since 2020—creating over 4,600 jobs and boosting domestic production of small molecule medicines.

API Manufacturing | 24/09/2025 | By Dineshwori |  339

Himachal Pradesh Bulk Drug Park in Una Secures Environmental Clearance, Set to Boost API Manufacturing

The Bulk Drug Park at Una in Himachal Pradesh has received environmental clearance from the Union Ministry of Environment, Forest and Climate Change, a key milestone for India’s pharmaceutical infrastructure.

API Manufacturing | 13/09/2025 | By Darshana |  606

Cohance's Jaggaiahpet API Plant Clears USFDA Inspection with Zero 483 Observations

The United States Food and Drug Administration (USFDA) has completed a general current Good Manufacturing Practices (cGMP) audit at Cohance Lifesciences' API manufacturing facility (API Unit1) located at Jaggaiahpet, Andhra Pradesh, with zero Form 483 observations.

API Manufacturing | 12/09/2025 | By Dineshwori |  434

AbbVie to Invest USD 195 Million to Expand API Manufacturing in US

AbbVie will invest USD 195 million to expand active pharmaceutical ingredient manufacturing at its North Chicago plant, strengthening US production capacity for current and next-generation medicines.

API Manufacturing | 13/08/2025 | By Mrinmoy Dey |  138